Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Evommune, Inc.

Ticker
EVMN
Sector
Industry
Report date
November 12, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include licensing an experimental arthritis drug with a $30 million funding raise, mixed clinical trial results with a failed Phase 2b trial for EVO756 and positive Phase 2a results for EVO301, and ongoing financial and operational updates.

Recent developments:
  • Evommune licensed an experimental arthritis drug and raised $30 million to fund its development in November 2026 [N2].
  • The company’s Phase 2b trial of EVO756 failed to meet its primary endpoint, leading to a decline in stock price in June 2026 [N6][N5].
  • Evommune reported strong Phase 2a results for EVO301, meeting the primary endpoint in atopic dermatitis in February 2026 [N10][N11].
  • The company reported a net loss of $28.27 million in Q4 2025 and a net loss of $30.88 million for Q3 2026 [N12][S2].
  • Evommune completed its IPO in November 2025, raising approximately $157 million in net proceeds [S1].
  • Insider buying activity was reported in July 2026 [N4].
  • The company has been described as a high-risk, high-reward healthcare stock in early 2026 [N13].
Overview

Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies targeting key drivers of chronic inflammatory diseases such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company’s pipeline includes two main product candidates, EVO756 and EVO301, both in Phase 2 clinical development. Evommune’s business model centers on advancing these candidates through clinical trials and regulatory approval, supported by strategic licensing and collaboration agreements with companies including Dermira, Maruho, and AprilBio. The company completed its initial public offering in November 2025, raising net proceeds of approximately $157 million, which have been invested primarily in secure financial instruments. Evommune has incurred significant operating losses since inception and continues to invest heavily in research and development. The company maintains strong liquidity as of the latest quarter ended September 30, 2026, with cash, short-term investments, and current assets substantially exceeding current liabilities. Recent clinical developments include positive Phase 2a results for EVO301 in atopic dermatitis and a Phase 2b trial failure for EVO756 in chronic spontaneous urticaria. The company also licensed an experimental arthritis drug and raised $30 million to fund its development in late 2026. Evommune’s operations include leased laboratory and office facilities in Palo Alto and New York, and it maintains cybersecurity risk management overseen by senior management and the board of directors.

Executive summary

Evommune, Inc. is a clinical-stage biotech company developing therapies targeting chronic inflammatory diseases, with two main product candidates in Phase 2 trials. The company has strategic licensing agreements and collaborations, including with Dermira, Maruho, and AprilBio. It completed an IPO in November 2025, raising approximately $157 million. As of September 30, 2026, Evommune reported a net loss of $30.88 million and held strong liquidity with a current ratio of 8.52. Recent clinical results include positive Phase 2a data for EVO301 and a failed Phase 2b trial for EVO756. The company licensed an experimental arthritis drug and raised $30 million for its development in November 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for EVMN

Bull case model:

Evommune’s differentiated product candidates targeting chronic inflammatory diseases have demonstrated promising clinical activity, notably EVO301’s positive Phase 2a results in atopic dermatitis. Strategic collaborations with established partners such as Dermira and Maruho provide financial resources and regional development expertise. The company’s strong liquidity position supports ongoing clinical development and potential expansion of its pipeline. Licensing an experimental arthritis drug and securing additional funding demonstrates the company’s ability to diversify its portfolio and attract capital. If clinical programs advance successfully, Evommune could establish a competitive position in multiple chronic inflammatory disease markets.

Bear case model:

Evommune faces significant clinical and regulatory risks, exemplified by the failure of EVO756’s Phase 2b trial to meet its primary endpoint, which negatively impacted investor sentiment. The company has incurred substantial operating losses and depends on external financing to fund operations, with no current product revenue. Clinical development timelines and outcomes are uncertain, and failure to achieve regulatory approvals would materially impact the business. The company’s reliance on licensing agreements entails milestone and royalty payment obligations that could affect future financial flexibility. Additionally, competition in the chronic inflammatory disease space is intense, and Evommune’s ability to commercialize products independently or through partners remains unproven.

Moat:

Evommune’s moat is primarily based on its proprietary clinical-stage product candidates targeting chronic inflammatory diseases, supported by exclusive licensing agreements with Dermira, Maruho, and AprilBio. These agreements provide the company with rights to develop and commercialize differentiated therapies in key geographic markets, including Japan and Greater Asia. The company’s focus on chronic inflammatory diseases addresses significant unmet medical needs, and its pipeline includes candidates with potential broad application across multiple indications. Evommune’s accumulated clinical data, intellectual property portfolio, and strategic collaborations contribute to barriers for competitors. However, as a clinical-stage biotech company without approved products, its moat is contingent on successful clinical development and regulatory approvals.

Risks overview
Risks summary
The primary risks for Evommune relate to clinical development uncertainties, financial sustainability, and regulatory approval challenges inherent to clinical-stage biotechnology companies.
Risks details:

• Clinical Development Risk: Failure of clinical trials to meet endpoints, as seen with EVO756 Phase 2b trial, poses a risk to product advancement and future revenue potential.
• Financial Risk: Continued operating losses and dependence on external financing create risks related to capital availability and sustaining operations.
• Regulatory Risk: Obtaining regulatory approvals for product candidates is uncertain and may involve delays or additional requirements.
• Competitive Risk: The chronic inflammatory disease market is competitive with multiple established and emerging therapies.
• Licensing and Collaboration Risk: Obligations under license agreements, including milestone and royalty payments, may impact financial flexibility and operational control.

FINAL FORECAST FOR EVMN

Final take one line
Evommune is a clinical-stage biotech with strong visibility into its inflammatory disease pipeline, strategic collaborations, and financial position, facing typical clinical and financial risks.
Final take 12 to 24 month view

Business trends: Advancement of clinical-stage product candidates EVO756 and EVO301 with ongoing licensing and portfolio expansion efforts.
Execution milestones: Completion of clinical trials, regulatory submissions, and potential commercialization partnerships.
Key risks: Clinical trial failures, regulatory hurdles, financial sustainability, and competitive pressures in chronic inflammatory disease markets.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies targeting chronic inflammatory diseases including chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC).
  • The company has two main product candidates in Phase 2 development: EVO756 (for CSU and AD) and EVO301 (for AD and UC).
  • Evommune was incorporated in April 2020 and has two wholly owned subsidiaries: Evommune Research, LLC and Evommune Biologics, LLC.
  • The company has incurred significant operating losses since inception, with an accumulated deficit of $221.1 million as of December 31, 2025, and net losses continuing through Q3 2026.
  • Evommune has not generated revenue from product sales and does not expect to generate product sales revenue in the near term; its revenue to date has been exclusively from license agreements.
  • The company has strategic collaborations and license agreements including with Dermira, Inc. (license for EVO756), Maruho Co., Ltd. (exclusive license for EVO756 in Japan and Greater Asia), and AprilBio Co., Ltd. (license for EVO301).
  • Evommune paid upfront license fees and milestone payments under these agreements and may owe further milestone and royalty payments contingent on development and sales.
  • The company completed its IPO on November 6, 2025, raising net proceeds of approximately $157 million, which have been invested primarily in U.S. Treasury securities, corporate bonds, and money market accounts.
  • As of September 30, 2026, Evommune had cash and equivalents of $47.57 million, short-term investments of $121.07 million, current assets of $174.56 million, and current liabilities of $20.48 million, resulting in a current ratio of 8.52 and a cash ratio of 8.23, indicating strong liquidity.
  • The company reported a net loss of $30.88 million and basic and diluted EPS of -$0.85 for the quarter ended September 30, 2026.
  • Recent clinical trial results include strong Phase 2a results for EVO301 meeting the primary endpoint in atopic dermatitis, and a Phase 2b trial of EVO756 failing to meet its primary endpoint in chronic spontaneous urticaria, which negatively impacted the stock price.
  • Evommune licensed an experimental arthritis drug and raised $30 million to fund its development in November 2026.
  • The company’s board oversees cybersecurity risk management, with dedicated senior IT leadership and incident response processes.
  • Evommune leases laboratory and office facilities in Palo Alto, California, and New York, with leases extended or newly signed through 2031.
  • The company’s operating expenses primarily consist of research and development and general and administrative costs, including personnel, consultants, license agreements, and clinical trial costs.
  • Evommune’s business model relies on advancing clinical-stage product candidates through development and regulatory approval, with plans to commercialize products independently or via collaborations.
  • The company’s financial disclosures are summarized from the latest SEC filings and provided for informational purposes only.
Sources
Sources - Context summary

Generated 2026-11-12

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-05 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-12 | www.nasdaq.com | Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/pelthos-therapeutics-inc-pths-reports-q3-loss-lags-revenue-estimates
  • N2 | 2026-11-07 | www.nasdaq.com | Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development | https://www.nasdaq.com/articles/evommune-licenses-experimental-arthritis-drug-raises-30-million-fund-development
  • N3 | 2026-07-13 | www.nasdaq.com | Evommune Becomes Oversold (EVMN) | https://www.nasdaq.com/articles/evommune-becomes-oversold-evmn
  • N4 | 2026-07-09 | www.nasdaq.com | Thursday 7/9 Insider Buying Report: LRMR, EVMN | https://www.nasdaq.com/articles/thursday-7-9-insider-buying-report-lrmr-evmn
  • N5 | 2026-06-30 | www.nasdaq.com | EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal | https://www.nasdaq.com/articles/evmn-stock-tanks-phase-iib-urticaria-study-misses-primary-goal
  • N6 | 2026-06-29 | www.nasdaq.com | Evommune's Phase 2b Trial Of EVO756 Fails To Meet Primary Endpoint, Stock Falls | https://www.nasdaq.com/articles/evommunes-phase-2b-trial-evo756-fails-meet-primary-endpoint-stock-falls
  • N7 | 2026-03-18 | www.nasdaq.com | Clear Street Initiates Coverage of Evommune (EVMN) with Buy Recommendation | https://www.nasdaq.com/articles/clear-street-initiates-coverage-evommune-evmn-buy-recommendation
  • N8 | 2026-03-10 | www.nasdaq.com | 1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade | https://www.nasdaq.com/articles/1-under-radar-biotech-buy-potential-10x-growth-next-decade
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine